Open-Label Study to Determine the Feasibility of MLN9708 as Maintenance After Allogeneic Stem Cell Transplant for Multiple Myeloma, Followed by an Expansion Phase at the Maximum-Tolerated Dose (MTD) - A Phase II Study
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 31 May 2019
Price : $35 *
At a glance
- Drugs Ixazomib (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions
- Sponsors SCRI Development Innovations
- 28 May 2019 Planned End Date changed from 1 Jan 2019 to 31 Jan 2020.
- 28 May 2019 Planned primary completion date changed from 1 Jan 2019 to 31 Jan 2020.
- 28 Feb 2018 Status changed from recruiting to active, no longer recruiting.